<div id="readability-page-1"><p>Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) reached a new 52-week high on Monday after Piper Sandler raised their price target on the stock from $30.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $30.98 and last traded at $30.9730, with a volume of 1205448 shares trading hands. The stock had previously closed at $30.35.</p><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>TEVA has been the subject of a number of other research reports. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $35.00 target price on the stock. JPMorgan Chase &amp; Co. lifted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $32.88.</p><p><b>View Our Latest Report on TEVA</b></p><h2>Insider Activity</h2><ul><li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li></ul><p>In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares of the company's stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company's stock, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last three months. 0.55% of the stock is currently owned by insiders. </p><h2>Institutional Investors Weigh In On Teva Pharmaceutical Industries</h2><p>A number of hedge funds have recently modified their holdings of TEVA. Advisors Asset Management Inc. purchased a new position in shares of  Teva Pharmaceutical Industries in the second quarter worth $41,000.  Cromwell Holdings LLC grew its position in shares of  Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock valued at $44,000 after purchasing an additional 629 shares in the last quarter.  Sound Income Strategies LLC increased its holdings in shares of  Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter.  MAI Capital Management increased its holdings in shares of  Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company's stock worth $55,000 after purchasing an additional 697 shares during the last quarter.  Finally, Rothschild Investment LLC lifted its position in shares of  Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after buying an additional 1,348 shares in the last quarter. Institutional investors own  54.05% of the company's stock. </p><h2>Teva Pharmaceutical Industries Stock Performance</h2><ul><li>2 Generic Drug Stocks Ready to Surge in 2025</li></ul><p>The business has a 50 day moving average of $24.44 and a 200 day moving average of $20.08. The company has a market capitalization of $35.55 billion, a P/E ratio of 51.62, a price-to-earnings-growth ratio of 1.81 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. </p><h2>About Teva Pharmaceutical Industries</h2> (Get Free Report)<p>Teva Pharmaceutical Industries Ltd. <span>NYSE: TEVA<span></span></span> is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.  </p><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Teva Pharmaceutical Industries</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>Do not delete, read immediately</li><li>How Long Will $1M Last in Retirement?</li><li>Buy this $2 Gold Stock Before January 1, 2026</li><li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TEVA

<p>Teva Pharmaceutical Industries (NYSE:TEVA) reached a new 52-week high after Piper Sandler raised their price target from $30.00 to $40.00, maintaining an overweight rating. Other analysts, including Goldman Sachs and UBS, also raised their price targets. Insider trading activity showed significant stock sales by company executives. Institutional investors have increased their holdings. The company has a market cap of $35.55 billion and a P/E ratio of 51.62.</p>

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High on Analyst Upgrade